US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status
- PMID: 24777111
- PMCID: PMC4580552
- DOI: 10.1093/jnci/dju055
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status
Abstract
Background: In 2010, Surveillance, Epidemiology, and End Results (SEER) registries began collecting human epidermal growth factor 2 (HER2) receptor status for breast cancer cases.
Methods: Breast cancer subtypes defined by joint hormone receptor (HR; estrogen receptor [ER] and progesterone receptor [PR]) and HER2 status were assessed across the 28% of the US population that is covered by SEER registries. Age-specific incidence rates by subtype were calculated for non-Hispanic (NH) white, NH black, NH Asian Pacific Islander (API), and Hispanic women. Joint HR/HER2 status distributions by age, race/ethnicity, county-level poverty, registry, stage, Bloom-Richardson grade, tumor size, and nodal status were evaluated using multivariable adjusted polytomous logistic regression. All statistical tests were two-sided.
Results: Among case patients with known HR/HER2 status, 36810 (72.7%) were found to be HR(+)/HER2(-), 6193 (12.2%) were triple-negative (HR(-)/HER2(-)), 5240 (10.3%) were HR(+)/HER2(+), and 2328 (4.6%) were HR(-)/HER2(+); 6912 (12%) had unknown HR/HER2 status. NH white women had the highest incidence rate of the HR(+)/HER2(-) subtype, and NH black women had the highest rate of the triple-negative subtype. Compared with women with the HR(+)/HER2(-) subtype, triple-negative patients were more likely to be NH black and Hispanic; HR(+)/HER2(+) patients were more likely to be NH API; and HR(-)/HER2(+) patients were more likely to be NH black, NH API, and Hispanic. Patients with triple-negative, HR(+)/HER2(+), and HR(-)/HER2(+) breast cancer were 10% to 30% less likely to be diagnosed at older ages compared with HR(+)/HER2(-) patients and 6.4-fold to 20.0-fold more likely to present with high-grade disease.
Conclusions: In the future, SEER data can be used to monitor clinical outcomes in women diagnosed with different molecular subtypes of breast cancer for a large portion (approximately 28%) of the US population.
Published by Oxford University Press 2014.
Figures
Comment in
-
Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.J Natl Cancer Inst. 2014 Apr 28;106(5):dju093. doi: 10.1093/jnci/dju093. J Natl Cancer Inst. 2014. PMID: 24777110 Free PMC article. No abstract available.
Similar articles
-
Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.Cancer Epidemiol. 2014 Oct;38(5):556-62. doi: 10.1016/j.canep.2014.08.001. Epub 2014 Sep 22. Cancer Epidemiol. 2014. PMID: 25172158
-
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101. doi: 10.1093/jnci/djs264. Epub 2012 Jul 5. J Natl Cancer Inst. 2012. PMID: 22773826 Free PMC article.
-
Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.JAMA Netw Open. 2020 Oct 1;3(10):e2020303. doi: 10.1001/jamanetworkopen.2020.20303. JAMA Netw Open. 2020. PMID: 33074325 Free PMC article.
-
Breast cancer in African-American women: differences in tumor biology from European-American women.Cancer Res. 2006 Sep 1;66(17):8327-30. doi: 10.1158/0008-5472.CAN-06-1927. Cancer Res. 2006. PMID: 16951137 Review.
-
Breast cancer: incidence, mortality, and early detection in Louisiana, 1988-1997.J La State Med Soc. 2001 Apr;153(4):198-209. J La State Med Soc. 2001. PMID: 11394331 Review.
Cited by
-
Explainable breast cancer molecular expression prediction using multi-task deep-learning based on 3D whole breast ultrasound.Insights Imaging. 2024 Sep 19;15(1):227. doi: 10.1186/s13244-024-01810-9. Insights Imaging. 2024. PMID: 39320560 Free PMC article.
-
Omission of axillary surgery in cN0, postmenopausal ER-positive/HER2-negative breast cancer patients undergoing breast-conserving treatment.Gland Surg. 2024 Aug 31;13(8):1408-1417. doi: 10.21037/gs-24-146. Epub 2024 Aug 28. Gland Surg. 2024. PMID: 39282037 Free PMC article.
-
PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study.BMC Cancer. 2024 Sep 10;24(1):1127. doi: 10.1186/s12885-024-12867-6. BMC Cancer. 2024. PMID: 39256703 Free PMC article.
-
Epidemiology and clinical characteristics of breast cancer in Ethiopia: a systematic review.BMC Cancer. 2024 Sep 4;24(1):1102. doi: 10.1186/s12885-024-12822-5. BMC Cancer. 2024. PMID: 39232684 Free PMC article.
-
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer.Geburtshilfe Frauenheilkd. 2024 Sep 2;84(9):813-836. doi: 10.1055/a-2344-5269. eCollection 2024 Sep. Geburtshilfe Frauenheilkd. 2024. PMID: 39229634 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous